WHAT THIS STUDY ADDS
arrhythmia
REGRESSION, HYPERTROPHIC CARDIOMYOPATHY, ARRHYTHMIA
The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy (TEMPEST) is a multicentre, double-blind, randomised, placebo-controlled phase II trial designed to evaluate the efficacy and mechanism of action of trientine in HCM.Primary outcome is change in LV mass indexed to body surface area. Secondary outcomes include exercise capacity and arrhythmia burden.Mechanistic objectives will determine whether the effects are mediated by cellular or extracellular mass regression and improved myocardial energetics.